NCT05307731View on ClinicalTrials.gov

Fingolimod for Type 2 Diabetes Mellitus

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2026

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Fingolimod

0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM

DRUG

guideline-based treatment for DM

guideline-based treatment for DM

Trial Locations (1)

110016

RECRUITING

Department of Neurology, General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors
lead

General Hospital of Shenyang Military Region

OTHER

NCT05307731 - Fingolimod for Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter